- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05544253
Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC
September 14, 2022 updated by: Jiwei Huang, West China Hospital
Safety and Efficacy of Mitomycin C-based Hyperthermic Intraperitoneal Chemotherapy After Spontaneously Ruptured Hepatocellular Carcinoma and Peritoneal Metastasis: a Randomized Controlled Trial
Hepatocellular carcinoma (HCC) is featured by the spontaneously rupture when suffering severe cirrhosis and intratumoral overpressure.
It is a fatal complication with an acute mortality.
Importantly, it is served as an independent risk factor for peritoneal metastasis (PM) of HCC with poor prognosis.
The systematic agents effective to extrahepatic lesions confers modest efficacy towards PM.
HIPEC, as a novel strategy, has been proved by overwhelming studies that it is effective to peritoneal malignant tumors.
However, there is absence of prospective study of HIPEC efficacy towards HCC.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
68
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jiwei Huang, Professor
- Phone Number: +86 18980606725
- Email: huangjiwei@wchscu.cn
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China
- Recruiting
- West China Hospital
-
Contact:
- Jiwei Huang, Professor
- Phone Number: +86 18980606725
- Email: huangjiwei@wchscu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HCC patients have been diagnosed by NCCN clinical practice guidelines in oncology, Hepatobiliary cancers, version 2.2021.
- ECOG score of 0-2 points;
- Child-Pugh class A-B liver function only;
- Consistent with the diagnosis of srHCC: symptoms: acute abdominal pain and peritonitis; blood routine tests: decrease of erythrocyte count; increase of leucocyte count, especially the proportion of neutrophils; radiological features: contrast materials extravasation from lesions confirmed by abdominal contrast enhanced computed tomography or promethean magnetic resonance imaging; intraoperative findings of tumor rupture and postoperative pathology are more confidently conclusive.
- Consistent with PM of HCC: histological evaluations: biopsy of peritoneal nodules or ascites cytology or postoperative pathological verification; radiological diagnose: early enhancement and late wash-out radiological property of peritoneal nodule or mutual confirmation by two senior radiologists.
- All of selections have received open or laparoscopic hepatectomy to reach complete macroscopic resection or less than 2.5mm of residual tumor tissue, which is equal to 0 or 1 degree of completeness of cytoreduction.
- Patients voluntarily participated and signed the informed consent.
Exclusion Criteria:
- Contraindications of HIPEC, such as: extensive intra-abdominal adhesions caused by various reasons; complete intestinal obstruction; severe kidney insufficiency; myelosuppression caused by previous targeted therapy or own blood system disease; severe cardiovascular system disease; infection, especially abdominal infection; bleeding tendency or coagulation dysfunction; the vital signs are unstable; cachexia;
- Extraperitoneal metastasis;
- Patients who refuse to accept clinical trials;
- Those who are deemed unsuitable for inclusion by the researchers.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HIPEC group
|
The patients with srHCC or PM of HCC were randomly allocated to either the HIPEC group or the control group.
All of them have received open liver resection and perfusion tubes had been set in the operation.
For patients with PM of HCC served operation, we are subject to reach CC score at 0-1 to creating sufficient conditions for HIPEC.
Finally, place the HIPEC tubes.
Implementation of HIPEC was administered 3times on the 1st, 3rd, 5th days within one week after operation.
We used intraperitoneal hyperthermic perfusion device (BR-TRG-IITM, Bao Rui medical corporation, Guangdong, China) to achieve HIPEC.
The abdominal temperature was maintained at 43°C (109°F) by circulating heated saline.
The perfusion volume was 3000ml of normal saline, and the chemotherapeutic agent of mitomycin C was 10mg for a 1-hour perfusion period.
|
No Intervention: non-HIPEC group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
recurrence-free-survival
Time Frame: 2years
|
the time from the first administration to the date of first recurrence, including local recurrence and PM and distant metastasis, or death for any cause.
|
2years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 1, 2022
Primary Completion (Anticipated)
September 1, 2024
Study Completion (Anticipated)
September 1, 2024
Study Registration Dates
First Submitted
September 10, 2022
First Submitted That Met QC Criteria
September 14, 2022
First Posted (Actual)
September 16, 2022
Study Record Updates
Last Update Posted (Actual)
September 16, 2022
Last Update Submitted That Met QC Criteria
September 14, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Neoplastic Processes
- Carcinoma
- Carcinoma, Hepatocellular
- Neoplasm Metastasis
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Alkylating Agents
- Antibiotics, Antineoplastic
- Mitomycins
- Mitomycin
Other Study ID Numbers
- JHuang
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HCC
-
University of PisaAzienda Ospedaliera Città della Salute e della Scienza di Torino; Fondazione... and other collaboratorsRecruiting
-
Seoul National University HospitalPhilips HealthcareCompleted
-
Huazhong University of Science and TechnologyUnknown
-
Taipei Medical University WanFang HospitalTerminated
-
Leiden University Medical CenterMedtronic; ZonMw: The Netherlands Organisation for Health Research and Development and other collaboratorsCompletedHCC | Early Stage HCCNetherlands
-
Qianfoshan HospitalNot yet recruiting
-
Xuhua DuanRecruiting
-
Ain Shams UniversityCompleted
-
Shenyang Tenth People's HospitalBeijing Tsinghua Changgeng HospitalNot yet recruiting
Clinical Trials on mitomycin C-based hyperthermic intraperitoneal chemotherapy
-
Tata Memorial CentreRecruitingColorectal Cancer | Ovarian Cancer | Peritoneal DiseaseIndia
-
Guangdong Provincial Hospital of Traditional Chinese...UnknownStage IV Gastric Cancer With Metastasis | Hyperthermic Intraperitoneal Chemotherapy | Exploratory BehaviorChina
-
The Affiliated Hospital of Qingdao UniversityThe First Affiliated Hospital of Nanchang University; Wuhan University; Peking... and other collaboratorsRecruiting
-
CHU de ReimsCompleted
-
Albert Einstein College of MedicineCompletedGastric Cancer | Colorectal Cancer | Pseudomyxoma Peritonei | Peritoneal Carcinomatosis | Peritoneal Mesothelioma | Appendiceal CancerUnited States
-
Memorial Sloan Kettering Cancer CenterMayo Clinic; University of Chicago; University of Pittsburgh; Baptist Health South... and other collaboratorsActive, not recruitingOvarian Cancer | Peritoneal Cancer | Fallopian Tubes CancerUnited States
-
University Hospital, RouenRecruiting
-
Weill Medical College of Cornell UniversityCompleted
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityShenshan Medical Center, Memorial Hospital of Sun Yat-sen UniversityNot yet recruitingEpithelial Ovarian CancerChina
-
Hospices Civils de LyonCompletedOvarian Cancer | Peritoneal CarcinomaFrance